Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
Eisai said on March 9 that France-based Ipsen, which holds the rights to the anticancer drug Tazverik (tazemetostat) outside Japan, has decided to voluntarily withdraw the product from overseas markets following safety concerns raised in a clinical trial. The decision…
To read the full story
Related Article
- Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
March 19, 2026
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
BUSINESS
- Eylea Bio-AG Snags 60% Share in Just 3 Months, Outpacing Biosimilar
May 29, 2026
- FRONTEO, Scohia Team Up on AI-Driven Indication Discovery
May 29, 2026
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…